ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
95,586.12
3.43%
S&P 500
5,844.57
-1.24%
Dow Jones
42,065.64
-1.34%
US Dollar vs Yen
157.669
-0.26%
Brent Oil
79.075
2.79%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) ニュース

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ELTX
日付受信時刻ニュースソース見出しコード企業名
2025/01/0806 : 30Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ELTXElicio Therapeutics Inc
2024/12/1906 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/12/1221 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/12/1221 : 00GlobeNewswire Inc.Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024NASDAQ:ELTXElicio Therapeutics Inc
2024/12/0321 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/12/0321 : 00GlobeNewswire Inc.Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentNASDAQ:ELTXElicio Therapeutics Inc
2024/11/2521 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/11/2521 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/11/2222 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELTXElicio Therapeutics Inc
2024/11/2206 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/11/2114 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
2024/11/1406 : 21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
2024/11/1406 : 05GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
2024/11/0806 : 27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/11/0806 : 05GlobeNewswire Inc.Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
2024/11/0723 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/10/3121 : 30GlobeNewswire Inc.Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation SummitNASDAQ:ELTXElicio Therapeutics Inc
2024/10/1721 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
2024/10/1621 : 30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
2024/10/0305 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/10/0305 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/10/0305 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
2024/09/2805 : 42Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELTXElicio Therapeutics Inc
2024/09/2805 : 41Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
2024/09/1805 : 05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
2024/09/1721 : 31GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
2024/09/1321 : 30GlobeNewswire Inc.Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile VaccinesNASDAQ:ELTXElicio Therapeutics Inc
2024/08/2821 : 00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
2024/08/1405 : 30GlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
2024/08/1305 : 05GlobeNewswire Inc.Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible NoteNASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
FX
USDJPY
US Dollar vs Yen
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
NASDAQ
NVDA
NVIDIA
CCOM
US100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
RHHBY
Roche (QX)
NASDAQ
GOOGL
Alphabet
COIN
AVAXUSD
Avalanche
CCOM
US500
US 500
NYSE
NKE
Nike
CCOM
US30
US 30
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有